Filler for marionette lines: identify the fold before choosing the product
A marionette line runs downward from the mouth corner, but a shadow in that area may also reflect corner position or prejowl contour. Product labeling and lower-face studies do not establish one filler or placement as best for every pattern.
Filler can be considered for a true marionette fold, but “marionette line” is not a complete treatment plan or a universal FDA-approved site claim for every syringe. The downward fold from the mouth corner may coexist with a downturned corner, prejowl shadow or chin-jawline contour issue; those are different targets. FDA records and lower-face studies attach to exact products, anatomy and endpoints. Ask a provider to mark the dominant feature and explain why the proposed product and site fit it.1234
This question has a different answer from a nasolabial fold beside the nose or fine vertical lines above the upper lip. Combining all three into “mouth lines” can lead to an oversized quote and an endpoint no one has defined.
Map the lower-face feature first
| Visible feature | Primary question | Why one filler quote may miss it |
|---|---|---|
| Downward fold from mouth corner toward chin | Is the concern a crease/shadow along the marionette path? | A product and outcome must match that fold |
| Mouth corner turns downward with expression or at rest | Is corner position the main visual issue? | Adding volume to a nearby fold may not address movement or position |
| Hollow or break beside the jaw/chin | Is prejowl or chin-jawline contour dominant? | A jawline endpoint is not the same as a marionette-fold endpoint |
| Fine vertical lines at upper lip | Are these perioral rhytids instead? | They involve a different site and product-specific evidence |
The table is an observation aid, not a home diagnosis. A clinician must assess tissue position, dynamic movement, previous filler, skin, teeth/dental context where relevant, and the person’s goal. A photograph taken with a broad smile may exaggerate or hide a different feature from the one seen at rest.
Read the label with the exact feature in view
Restylane Defyne’s FDA instructions describe correction of moderate-to-severe deep facial wrinkles and folds, such as nasolabial folds, in adults over 21. That is not a sentence saying every filler is approved to correct every marionette line. A separate Juvéderm Volux XC regulatory study included a lower-face injection pattern involving the marionette area, but its approval endpoint concerned jawline definition, not a standalone marionette-line claim.12
FDA product status and clinician-directed off-label use are separate questions. If a practice says its exact marionette treatment is FDA approved, ask for the finished product’s current IFU and the line supporting that site and outcome. If the use is off-label, it should be described accurately, with an evidence and risk discussion—not hidden behind an ingredient-level “FDA approved filler” badge.
What the lower-face studies can and cannot tell you
A randomized postmarket Defyne study compared sequencing in a combined chin-and-fold plan. It can inform questions about how a lower-face plan was assessed, but it does not compare filler with no treatment or establish that chin-first is best for every face. An open-label VYC-17.5L marionette study adds a product-specific observation, but without an untreated randomized comparator it cannot isolate all changes or rank products.34
Ask which scale or photo standard the study used, how long participants were followed and whether the proposed plan resembles the trial’s anatomy and product. A provider gallery can show aesthetic style; it does not substitute for product-specific outcome evidence or confirm that the same feature was treated.
Make the consultation one decision at a time
Have the provider identify the dominant feature on an unretouched baseline photo and explain what part of a proposed plan addresses that feature. Request the product name, labeled or off-label site, expected endpoint, uncertainty, total quote and follow-up. If several areas are bundled, ask which can be evaluated separately and why the bundle is necessary. The safety plan should also account for FDA’s immediate-attention signs during or shortly after filler: unusual pain, vision change, white/gray/blue skin near the injection site, or stroke signs. Any one is enough to seek immediate medical attention.5
The nasolabial-fold article handles a different support question; the chin-filler comparison concerns projection and structural choice. For marionette lines, the most useful outcome is a clear feature-to-site-to-product explanation. A filler practice should be able to give one before asking a reader to buy syringes.
Sources
- U.S. Food and Drug Administration. Restylane Defyne instructions for use. Approved facial-wrinkle/fold wording and exact product limits; this IFU does not name a universal standalone marionette-line indication. Accessed .
- U.S. Food and Drug Administration. Juvéderm Volux XC summary of safety and effectiveness. Jawline-definition study included a lower-face injection pattern; its approved endpoint is jawline definition, not standalone marionette-line correction. Accessed .
- PubMed Central / original randomized lower-face study. Restylane Defyne lower-face treatment-sequencing study. Compared chin-first versus fold-first sequencing in a combined lower-face plan; not filler against no treatment or proof of one universal technique. Accessed .
- PubMed / original open-label study. VYC-17.5L for marionette-line correction. Marionette-specific prospective observations without an untreated randomized comparator; supports bounded discussion of an outcome measure. Accessed .
- U.S. Food and Drug Administration. Dermal Fillers (Soft Tissue Fillers). FDA lists unusual pain, vision change, white/gray/blue skin near the injection site, or stroke signs during or shortly after filler as separate immediate-attention warnings. Accessed .